EXPERIMENTAL HEMATOLOGY GROUP

CLINICAL RESEARCH
Experimental Hematology Group

FRANCESC BOSCH
Principal Investigator
Biosketch

VHIO’s Experimental Hematology Group conducts translational, pre-clinical and clinical research on hematological neoplasms of both lymphoid and myeloid origin. Our research team is composed of hematologists and biological scientists who work closely together to design, conduct and lead our programs. Our projects are always based on the unmet medical needs identified by hematologists, with the ultimate goal of translating our results to patients by developing early phase clinical trials and defining novel biomarkers to improve diagnosis, prognosis and outcomes.

We aim to provide new therapeutic options for our patients by deciphering the mechanisms involved in the pathogenesis and progression of hematological malignancies. We also conduct pre-clinical studies of new therapeutic proposals for patients diagnosed with hematological malignancies. Our group fosters the definition of new biomarkers in hematology that will lead to a more rational and precise diagnosis, prognosis and treatment of our patients.

Finally, the Hematology Clinical Trials Unit is currently participating in more than 103 clinical studies, including phase I clinical trials (n=25) and first-in-human studies of targeted therapies, both in lymphoid and myeloid malignancies. Last year 146 patients were included in our clinical trials, with 53 patients enrolled in phase I studies.

STRATEGIC GOALS

  • We translate preclinical findings into clinical benefit by developing early phase clinical trials and defining new prognostic and predictive factors.
  • Main research lines currently focus on:
    • Deciphering the mechanisms involved in pathogenesis and progression of hematological neoplasms.
    • The preclinical study of new therapeutic regimens in experimental models that mimic the tumoral microenvironment using primary cells and patient-derived xenograft (PDX) models.
    • Defining new biomarkers for a more rational and precise treatment of patients.

HIGHLIGHTS

  • In 2019 we have participated in the publication of 45 scientific papers, and as principal authors (first, last or corresponding) of 12 of these. 60% of these articles are published in journals in the first quartile, with an accumulative Impact Factor of 95.
  • This year we have initiated six new projects, four of which are supported through grants received from competitive calls, including La Fundació La Marató de TV3.

 


TEAM

  • Principal Investigator
    • Francesc Bosch
  • Translational Research Coordinator
    • Marta Crespo
  • Clinical Research Coordinator
    • Pau Abrisqueta
  • Lab Manager
    •  Júlia Carabia
  • Hematologists/Lead Investigators
    • Pere Barba
    • David Beneitez
    • Gael Roue
    • Amparo Santamaria,
    • David Valcárcel
  • Hematologists/Lab Specialists
    • Adoracion Blanco
    • Sabela Bobillo
    • Olga Benitez
    • Maria Cerda
    • Cecilia Carpio
    • Sally Franco
    • Maria Laura Fox
    • Laura Gallur
    • Mercedes Gironella
    • Gloria Hidalgo
    • Gloria Iacoboni
    • Macarena Izuzquiza
    • Marta Julia
    • Ana Marin
    • Maria Martinez
    • Alba Mesa
    • Antonieta Molero
    • Julia Montoro
    • Mayda Navarrete
    • Margarita Ortega
    • Guillem Orti
    • Ana Ortuño
    • Carles Palacio
    • Gloria Passarelli
    • Olga Salamero
    • Silvia Saumell
    • Milagros Suito
    • Barbara Tazon
    • Gustavo Robayo
    • Elisa Roldan
    • Marta Villalba
  • Phd Students
    • Sabela Bobillo
    • Júlia Carabia
    • Cecilia Carpio
    • Isabel Jiménez
    • Júlia Montoro
    • Guillermo Orti
  • Post-Doctoral Scientists
    • Juan Camilo Nieto
    • Diana Reyes
    • Marcelo Lima Ribeiro
  • Phd Students
    • Cristina Hernandez
    • Isabel Jimenez
    • Daniel Medina
    • Carlota Pages
  •  Technicians
    • Marc Antoni Armengol
    • Sergio Manresa
    • Magdalena Munuera
    • Lluis Puigdefàbregas

 


Most relevant scientific publications

  • Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Dec 6;132(23):2446-2455.
  • Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018 Aug;32(8):1778-1786.
  • Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017 Oct 1;28(10):2489-2495.
  • Purroy N, Carabia J, Abrisqueta P, Egia L, Aguiló M, Carpio C, Palacio C, Crespo M, Bosch F. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signalingin chronic lymphocytic leukemia cells. Oncotarget. 2017 Jan 3;8(1):742-756.
  • Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol. 2017 May 20;35(15):1668-1677.
  • Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529-3537.
  • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
  • Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
  • Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.

All publications

  • Chronic lymphocytic leukaemia: from genetics to treatment.Bosch F; Dalla-Favera R. 2019.Nat Rev Clin Oncol.16(11): 684 701.
  • Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G. 2019.J Clin Oncol.37(5): 367 367.
  • Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J. 2019.Blood.134(16): 1337 1345.
  • Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; NguyenKhac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; et al… 2019.Blood.133(11): 1205 1216.
  • Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.Schuster, S.J.; Bartlett, N.L.; Assouline, S.; Yoon, S.-S.; Bosch, F.; Sehn, L.H.; Cheah, C.Y.; Shadman, M.; Gregory, G.P.; Ku, M.; Wei, M.C.; Yin, S.; Kwan, A.; Yousefi, K.; Hernandez, G.; Li, C.-C.; O’Hear, C.; Budde, L.E.. 2019.Blood.134(1): 6 6.
  • Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?.Riveiro-Barciela M; Gironella M; Senín A; Salcedo MT; Merino-Casabiel X; Castells L; Esteban R; Buti M; Martínez-Valle F. 2019.Hepatology.69(6): 2701 2703.
  • Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D; EINSTEIN-Jr Phase 2 Investigators. 2019.LANCET HAEMATOL.6(10): 500 509.
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yagci M; et al…2019.LANCET HAEMATOL.6(2): 67 78.
  • Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G. 2019.Leukemia.33(8): 1996 2005.
  • Repurposing dasatinib for diffuse large B cell lymphoma.Scuoppo C; Wang J; Persaud M; Mittan SK; Basso K; Pasqualucci L; Rabadan R; Inghirami G; Grandori C; Bosch F; Dalla-Favera R. 2019.Proc Natl Acad Sci U S A.116(34): 16981 16986.
  • Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly A; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Sridharan A; Gueorguieva I; Girvan A; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Will B; Verma A. 2019.Clin Cancer Res.25(23): 6976 6985.
  • Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekhar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H. 2019.Clin Cancer Res.25(13): 3772 3775.
  • Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.Carrillo-Cruz E; García-Lozano JR; Márquez-Malaver FJ; Sánchez-Guijo FM; Montero Cuadrado I; Ferra I Coll C; Valcárcel D; López-Godino O; Cuesta M; Parody R; López-Corral L; Alcoceba M; Caballero-Velázquez T; Rodríguez-Gil A; Bejarano-García JA; Ramos TL; Pérez-Simón JA. 2019.Clin Cancer Res.25(15): 4616 4623.
  • Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature..Rodríguez-Otero P; Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Bargay J; Bengoechea E; González Y; de Oteyza JP; Gironella M; Nuñez-Córdoba JM; Encinas C; Martín J; Cabrera C; Palomera L; de Arriba F; Cedena MT; Puig N; Oriol A; Paiva B; Bladé J; Lahuerta JJ; San Miguel JF. 2019.BLOOD CANCER J.9(4): 36 36.
  • Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.Recasens-Zorzo C; Cardesa-Salzmann T; Petazzi P; Ros-Blanco L; Esteve-Arenys A; Clot G; Guerrero-Hernández M; Rodríguez V; Soldini D; Valera A; Moros A; Climent F; González-Barca E; Mercadal S; Arenillas L; Calvo X; Mate JL; Gutiérrez-García G; Casanova I; Mangues R; Sanjuan-Pla A; Bueno C; Menéndez P; Martínez A; Colomer D; Estrada-Tejedor R; Teixidó J; Campo E; López-Guillermo A; Borrell JI; Colomo L; Pérez-Galán P; Roué G2019.HAEMATOLOGICA.104(4): 778 788.
  • Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications..Reyes-Garau D; Ribeiro ML; Roué G2019.Cancers (Basel).11(10): 1483.
  • Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.Ribera JM; García O; Moreno MJ; Barba P; García-Cadenas I; Mercadal S; Montesinos P; Barrios M; González-Campos J; Martínez-Carballeira D; Gil C; Ribera J; Vives S; Novo A; Cervera M; Serrano J; Lavilla E; Abella E; Tormo M; Amigo ML; Artola MT; Genescà E; Bravo P; García-Belmonte D; García-Guiñón A; Hernández-Rivas JM; Feliu E; PETHEMA Group of the Spanish Society of Hematology. 2019.Cancer.125(16): 2810 2817.
  • Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). 2019.Br J Haematol.184(5): 797 807.
  • New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).Bento, L.; Díaz-López, A.; Barranco, G.; Martín-Moreno, A.M.; Baile, M.; Martín, A.; Sancho, J.M.; García, O.; Rodríguez, M.; Sánchez-Pina, J.M.; Novelli, S.; Salar, A.; Bastos, M.; Rodríguez-Salazar, M.J.; González de Villambrosia, S.; Córdoba, R.; García-Recio, M.; Martínez-Serra, J.; del Campo, R.; Luzardo, H.; García, D.; Hong, A.; Abrisqueta, P.; Sastre-Serra, J.; Roca, P.; Rodríguez, J.; Gutiérrez, A.. 2019.Br J Haematol..
  • Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia..Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E; Spanish Group of MDS (GESMD). 2019.Br J Haematol..
  • The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.Ribera J; Granada I; Morgades M; Vives S; Genescà E; González C; Nomdedeu J; Escoda L; Montesinos P; Mercadal S; Coll R; González-Campos J; Abella E; Barba P; Bermúdez A; Gil C; Tormo M; Pedreño M; Martínez-Carballeira D; Hernández-Rivas JM; Orfao A; Martínez-López J; Esteve J; Bravo P; Garcia-Guiñon A; Debén G; Moraleda JM; Queizán JA; Ortín X; Moreno MJ; Feliu E; Solé F; Ribera JM; PETHEMA Group, Spanish Society of Haematology. 2019.Br J Haematol.186(2): 263 268.
  • 1983 1995.
  • Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report.Ortí G; Iacoboni G; Barba P; Gimeno R; Roldán E; Fox LSalamero OBosch FValcárcel D2019.Bone Marrow Transplant.54(5): 772 774.
  • Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.Ortí G; García-Cadenas I; López L; Pérez A; Jimenez MJ; Sánchez-Ortega I; Alonso L; Sisinni L; Fox L; Villacampa G; Badell I; de Heredia CD; Parody R; Ferrà C; Solano C; Caballero D; Martino R; Querol S; Valcárcel D2019.Bone Marrow Transplant.54(7): 1133 1137.
  • Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study..Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti GValcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA; Grupo Español de Trasplante Hematopoyético (GETH). 2019.Bone Marrow Transplant..
  • Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V. 2019.Sci Rep.9(1): 16680 16680.
  • Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox LValcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL. 2019.Biol Blood Marrow Transplant.25(5): 1022 1030.
  • Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A; Grupo Español de Trasplante Hematopoyético (GETH). 2019.Biol Blood Marrow Transplant.25(9): 1825 1831.
  • Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G2019.Front Genet.10: 986 986.
  • Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial..Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group). 2019.Cancer Med.8(16): 6955 6966.
  • Off-pump technique and replacement therapy for coronary artery bypass surgery in a patient with hemophilia B.Fernández-Caballero M; Martinez MF; Oristrell G; Palmer N; Santamaría A2019.J Thromb Thrombolysis.48(2): 299 302.
  • Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology. 2019.Genes Chromosomes Cancer.58(11): 815 819.
  • Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.Caballero JC; Sánchez Barba M; Hernández Sánchez JM; Such E; Janusz K; Sanz G; Cabrero M; Chillón C; Cervera J; Hurtado AM; Jerez A; Calderón Cabrera C; Valcárcel D; Lumbreras E; Abáigar M; López Cadenas F; Hernández Rivas JM; Del Cañizo MC; Díez Campelo M. 2019.ANN HEMATOL.98(9): 2151 2162.
  • Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients..García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). 2019.ANN HEMATOL.98(2): 321 330.
  • An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups. 2019.Leuk Lymphoma.60(4): 1030 1035.
  • Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D.2019.Leuk Lymphoma.60(6): 1522 1527.
  • Real life outcomes of patients aged >= 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.Salamero O; Martínez-Cuadrón D; Sobas M; Benavente C; Vives S; De la Serna J; Pérez-Encinas M; Escoda L; Gil C; Brunet S; Ramos F; Esteve J; Amigo M; Krsnik I; Manso F; Arias J; González-Campos J; Serrano J; Oleksiuk J; Barrios M; García-Boyero R; Novo A; Sanz MA; Montesinos P; PETHEMA and PALG Groups. 2019.Leuk Lymphoma.60(11): 2720 2732.
  • Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols..Sobas M; Rodriguez-Veiga R; Vellenga E; Paluszewska M; De la Serna J; García-Álvarez F; Gil C; Brunet S; Bergua J; González-Campos J; Ribera JM; Tormo M; González M; Fernández I; Benavente C; González-Sanmiguel JD; Esteve J; Pérez-Encinas M; Salamero O; Manso F; Lowenberg B; Sanzs MA; Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups. 2019.EUR J HAEMATOL..
  • Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C; Spanish group of blood and marrow transplantation (GETH). 2019.EUR J HAEMATOL.102(6): 465 471.
  • Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.Barba P; Morgades M; Montesinos P; Gil C; Fox ML; Ciudad J; Moreno MJ; González-Campos J; Genescà E; Martínez-Carballeira D; Martino R; Vives S; Guardia R; Mercadal S; Artola MT; Cladera A; Tormo M; Esteve J; Bergua J; Vall-Llovera F; Ribera J; Martínez-Sanchez P; Amigo ML; Bermúdez A; Calbacho M; Hernández-Rivas JM; Feliu E; Orfao A; Ribera JM; PETHEMA Group. 2019.EUR J HAEMATOL.102(1): 79 86.
  • Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma..Jiménez-Segura R; Granell M; Gironella M; Abella E; García-Guiñón A; Oriol A; Cabezudo E; Clapés V; Soler JA; Escoda L; López-Pardo J; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Bladé J; Rosiñol L; GEMMAC (Grup per l l’estudi del mieloma mútiple i l’amiloïdosi de Catalunya). 2019.EUR J HAEMATOL.102(5): 389 394.
  • Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch FSantamaría A2019.J Comp Eff Res.8(3): 165 178.
  • Allogeneic stem cell transplantationin the era of novel therapies for acute lymphoblastic leukaemia..Barba P; Elorza I. 2019.Med Clin (Barc).153(1): 28 34.
  • Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjogren’s syndrome: which associated condition should be prioritized?.Pardos-Gea J; Martínez F; Abrisqueta PSantamaría ABosch F2019.Blood Coagul Fibrinolysis.30(5): 239 242.
  • “The TEAM Project” Results on Management of Placenta-Mediated Pregnancy Complications (PMC): The Impact of Thrombophilia Test and Thromboprophylaxis with Low-Molecular-Weight-Heparin on Recurrences of PMC.SANTAMARIA ORTIZ, AMPARO; Martí, Edelmira; Medina, Carmen; Rodríguez, Ana María; Stevenazzi, Mariana; Mira, Yolanda; López, Mertixell; Redondo, Ana Margarita; Aguinaco, Reyes; Sabater, María C; Oliver,
  • Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy..Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; Jiménez JL; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Rodriguez A; Lorza L; Martín A; Coria E; López-Guillermo A; Salar A; José Lahuerta J; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu. 2019.Hematol Oncol Stem Cell Ther.12(4): 194 203.
  • Thrombosis and hemostasis health in pregnancy: Registries from the International Society on Thrombosis and Haemostasis..Othman M; Santamaría Ortiz A; Cerdá M; Erez O; Minford A; Obeng-Tuudah D; Blondon M; Bistervels I; Middeldorp S; Abdul-Kadir R. 2019.Res Pract Thromb Haemost.3(4): 607 614.
  • Mateos, María-Victoria; Dimopoulos, Meletios A; Cavo, Michele; Suzuki, Kenshi; Jakubowiak, Andrzej; Knop, Stefan; Doyen, Chantal; Lucio, Paulo; Nagy, Zsolt; Kaplan, Polina; Pour, Ludek; Cook, Mark; Grosicki, Sebastian; Crepaldi, Andre; Liberati, Anna M; Campbell, Philip; Shelekhova, Tatiana; Yoon, Sung-Soo; Iosava, Genadi; Fujisaki, Tomoaki; Garg, Mamta; Chiu, Christopher; Wang, Jianping; Carson, Robin; Crist, Wendy; Deraedt, William; Nguyen, Huong; Qi, Ming; San-Miguel, Jesus; ALCYONE Trial Investigators; Fantl, Dorotea; Bar, Daniel; Riveros, Dardo Alberto; Jarchum, Gustavo; Enrico, Alicia Ines; Pavlovsky, Astrid; Jaksic, Wilfrid; Szer, Jeffrey; Murphy, Nick; Sadawarte, Sonali; Forsyth, Cecily; Blum, Robert; Ho, Joy; Mills, Anthony; Horvath, Noemi; Bries, Greet; Van Eygen, Koenraad; Wu, Ka Lung; Deeren, Dries; Van Steenweghen, Steven; Berneman, Zwi Nisan; Offner, Fritz; Mineur, Philippe; Schots, Rik; Hungria, Vania; Maciel, James; Maiolino, Angelo; Braga, Walter; Barbosa, Suzanna; Kaufman, Jacques; Barreto, Wolney; Oliveira, Luciana; Fogliatto, Laura; Castro, Nelson; Farias, Danielle; Santucci, Rodrigo; Hamerschlak, Nelson; Duarte, Fernando; Hadjiev, Evgueniy; Radinoff, Atanas; Tzvetkov, Nikolay; Gercheva-Kyuchukova, Liana; Mihaylov, Georgi; Yotov, Gancho; Raynov, Julian; Sivcheva, Liliya; Goranov, Stefcho; Kolonic, Slobodanka O; Skunca, Zeljka; Batinic, Josip; Pejsa, Vlatko; Spicka, Ivan; Gregora, Evzen; Scudla, Vastimil; Maisnar, Vladimir; Hajek, Roman; Jungova, Alexandra; Zodelava, Mamia; Gaprindashvili, Ekaterine; Fuhrmann, Stephan; Schleicher, Jan; Jakob, Christian; Dickinson, Joy Priscilla; Hindahl, Heidrun; Jacobs, Georg; Chaidos, Aristeidis; Crawley, Charles; Al-Rafaie, Faris; Sahu, Satyajit; Hamblin, Michael; Makkuni, Sudhakaran; Zhelyazkova, Antonina; Symeonidis, Argiris; Anagnostopoulos, A; Pappa, Vasiliki; Anargyrou, Konstantinos; Zikos, Panagiotis; Illes, Arpad; Szomor, Arpad; Masszi, Tamas; Mikala, Gabor; Rosta, Andras; Egyed, Miklos; Varga, Gergely; Rambaldi, Alessandro; Boccadoro, Mario; Palumbo, Antonio; Offidani, Massimo; Foa, Roberto; Rossi, Giuseppe; Cafro, Anna Maria; Musto, Pellegrino; Fabbiano, Francesco; Corso, Alessandro; di Raimondo, Francesco; Zambello, Renato; Gobbi, Marco; Nagafuji, Koji; Iida, Shinksuke; Matsumoto, Morio; Takezako, Naoki; Sunami, Kazutaka; Kosugi, Hiroshi; Ishikawa, Takayuki; Izutsu, Koji; Imada, Kazunori; Kaneko, Hitomi; Sugiura, Isamu; Shinagawa, Atsushi; Onishi, Yasushi; Takamatsu, Hiroyuki; Uchida, Toshiki; Matsue, Kousei; Wake, Atsushi; Aotsuka, Nobuyuki; Lee, Won Sik; Eom, Hyeon Seok; Kim, Ki Hyun; Kim, Sunghyun; Yoon, Dok Hyun; Lee, Jeeong-Ok; Kim, Jin Seok; Lee, Jae Hoon; Min, Chang-ki; Lee, Jejung; Stankovic, Svetlana; Georgievski, Borche; Chevreska, Lidija; Czyz, Jaroslaw; Kloczko, Janusz; Jedrzejczak, Wieslaw Wiktor; Homenda, Wojciech; Woszczyk, Dariusz; Holojda, Jadwiga; Hus, Marek; Hellmann, Andrzej; Wrobel, Tomasz; Walewski, Jan; Martins, Joana; Esteves, Graca; Martins, Angelo; Gheorghita, Emanuil; Borsaru, Gabriela; Popov, Viola Maria; Danaila, Catalin Doru; Lazaroiu, Mihaela; Alekseev, Sergey; Samoilova, Olga; Pristupa, Alexander; Udovitsa, Dmitry; Rossiev, Viktor; Afanasyev, Boris; Konstantinova, Tatiana; Samarina, Irina; Dunaev, Yurii; Kaplanov, Kamil; Milanovic, Nenad; Marjanovic, Goran; Marisavljevic, Dragomir; Jovanovic, Darjana; Milojevic, Zoran; Savic, Aleksander; Hernandez Garcia, Miguel Teodoro; De La Rubia, Javier; Couto Caro, Carmen; Perez de Oteyza, Jaime; Blade, Joan; Gonzales, Yolanda; Oriol, Albert; Rodriguez, Paula; Martin Sanchez, Jesus; Sole, Maria; de Arriba, Felipe; Sureda, Ana; Martinez, Joaquin; Alvarez Rivas, Miguel Angel; Gironella Mesa, Mercedes; Casado Montero, Luis Felipe; Encinas, Cristina; Palomera, Luis; Sastre Moral, Jose Luis; Yagci, Munci; Altuntas, Fevzi; Ozet, Gulsum; Ozsan, Guner Hayri; Vural, Filiz; Turgut, Mehmet; Turgut, Burhan; Ferhanoglu, Burhan; Bolaman, Ali Zahit; Besisik, Sevgi Kalayoglu; Unal, Ali; Beksac, Meral; Pylypenko, Halyna; Samura, Borys; Popovs’ka, Tetiana; Masliak, Zvenyslava; Glushko, Natalia; Rekhtman, Grygoriy; Moezi, Mehdi; de Lima, Marcos; Ehsan, Malek; Vaughn, Christopher; Roman, Eloy; Schiller, Gary; Jhangiani, Haresh; Wallace, Olukemi; Holden, Viran; Snider, Jessica; Noga, Stephen; Haile, David; Alraws, Anas. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine. 2018 Feb 08
  • Morschhauser, Franck; Fowler, Nathan H; Feugier, Pierre; Bouabdallah, Reda; Tilly, Hervé; Palomba, M Lia; Fruchart, Christophe; Libby, Edward N; Casasnovas, Rene-Olivier; Flinn, Ian W; Haioun, Corinne; Maisonneuve, Hervé; Ysebaert, Loic; Bartlett, Nancy L; Bouabdallah, Kamal; Brice, Pauline; Ribrag, Vincent; Daguindau, Nicolas; Le Gouill, Steven; Pica, Gian M; Martin Garcia-Sancho,Jean-François; Ando, Kiyoshi; Gomes da Silva, Maria; André, Marc; Zachée, Pierre; Sehn, Laurie H; Tobinai, Kensei; Cartron, Guillaume; Liu, David; Wang, Jianming; Xerri, Luc; Salles, Gilles A; RELEVANCE Trial Investigators; Abdel-Samad, Nizar; Abdo-Matkiwsky, May; Abraham, Julie; Abrisqueta Costa, Pau; et al.. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine. 2018 Sep 06
  • Flinn, Ian W; Hillmen, Peter; Montillo, Marco; Nagy, Zsolt; Illés, Árpád; Etienne, Gabriel; Delgado, Julio; Kuss, Bryone J; Tam, Constantine S; Gasztonyi, Zoltán; Offner, Fritz; Lunin, Scott; Bosch Albareda, Francesc; Davids, Matthew S; Lamanna, Nicole; Jaeger, Ulrich; Ghia, Paolo; Cymbalista, Florence; Portell, Craig A; Skarbnik, Alan P; Cashen, Amanda F; Weaver, David T; Kelly, Virginia M; Turnbull, Barry; Stilgenbauer, Stephan. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Des 06
  • Bosch Albareda, Francesc; Hallek, Michael. Venetoclax after idelalisib: relevant progress for CLL. Blood. 2018 Abr 12
  • Rodríguez-Otero, Paula; Mateos, María Victoria; Martínez-López, Joaquín; Martín-Calvo, Nerea; Hernández, Miguel-Teodoro; Ocio, Enrique M; Rosiñol, Laura; Martínez, Rafael; Teruel, Ana-Isabel; Gutiérrez, Norma C; Bargay, Joan; Bengoechea, Enrique; González, Yolanda; de Oteyza, Jaime Pérez; Gironella Mesa, Mercedes; Encinas, Cristina; Martín, Jesús; Cabrera, Carmen; Palomera, Luis; de Arriba, Felipe; Cedena, María Teresa; Paiva, Bruno; Puig, Noemí; Oriol, Albert; Bladé, Joan; Lahuerta, Juan José; San Miguel, Jesús F. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia. 2018 Nov 01
  • Martínez-Cuadrón, D; Montesinos, P; Vellenga, E; Bernal, T; Salamero Garcia, Olga; Holowiecka, A; Brunet, S; Gil, C; Benavente, C; Ribera, J M; Pérez-Encinas, M; De la Serna, J; Esteve, J; Rubio, V; González-Campos, J; Escoda, L; Amutio, M E; Arnan, M; Arias, J; Negri, S; Lowënberg, B; Sanz, M A. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia. 2018 Jan 01
  • Stilgenbauer, Stephan; Leblond, Veronique; Foà, Robin; Böttcher, Sebastian; Ilhan, Osman; Knauf, Wolfgang; Mikuskova, Eva; Renner, Christoph; Tausch, Eugen; Woszczyk, Dariusz; Gresko, Ekaterina; Lundberg, Linda; Moore, Tom; Morris, Thea; Robson, Susan; Bosch Albareda, Francesc. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018 Aug 01
  • Hernández-Boluda, J-C; Pereira, A; Correa, J-G; Alvarez-Larrán, A; Ferrer-Marín, F; Raya, J-M; Martínez-López, J; Pérez-Encinas, M; Estrada, N; Velez, P; Fox, M. Laura; García-Gutiérrez, V; Payer, A; Kerguelen, A; Cuevas, B; Durán, M-A; Ramírez, M-J; Gómez-Casares, M-T; Mata-Vázquez, M-I; Mora, E; Martínez-Valverde, C; Gómez, M; Cervantes, F. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2018 Feb 01
  • Arana, P; Paiva, B; Cedena, M-T; Puig, N; Cordon, L; Vidriales, M-B; Gutierrez, N C; Chiodi, F; Burgos, L; Anglada, L-L; Martinez-Lopez, J; Hernandez, M-T; Teruel, A-I; Gironella Mesa, Mercedes; Echeveste, M-A; Rosiñol, L; Martinez, R; Oriol, A; De la Rubia, J; Orfao, A; Blade, J; Lahuerta, J-J; Mateos, M-V; San Miguel, J-F. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia. 2018 Abr 01
  • Ruiz-Heredia, Yanira; Sànchez-Vega, Beatriz; Onecha, Esther; Barrio, Santiago; Alonso, Rafael; Martínez-Ávila, Jose Carlos; Cuenca, Isabel; Agirre, Xabier; Braggio, Esteban; Hernández, Miguel-T; Martínez, Rafael; Rosiñol, Laura; Gutierrez, Norma; Martin-Ramos, Marisa; Ocio, Enrique M; Echeveste, María Asunción; Pérez de Oteyza, Jaime; Oriol, Albert; Bargay, Joan; Gironella Mesa, Mercedes; Ayala, Rosa; Bladé, Joan; Mateos, María-Victoria; Kortum, Klaus M; Stewart, Keith; García-Sanz, Ramón; San Miguel, Jesús; Lahuerta, Juan José; Martinez-Lopez, Joaquín. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica. 2018 Nov 01
  • Bobillo Varelo, Sabela; Abrisqueta Costa, Pau; Carpio Segura, Cecilia; Raheja, Priyanka; Castellví, Josep; Crespo Maull, Marta; Bosch Albareda, Francesc. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018 Feb 01
  • Leblond, Véronique; Aktan, Melih; Ferra Coll, Christelle M; Dartigeas, Caroline; Kisro, Jens; Montillo, Marco; Raposo, João; Merot, Jean-Louis; Robson, Susan; Gresko, Ekaterina; Bosch Albareda, Francesc; Stilgenbauer, Stephan; Foà, Robin. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 2018 Nov 01
  • Genescà, E; Lazarenkov, A; Morgades, M; Berbis, G; Ruíz-Xivillé, N; Gómez-Marzo, P; Ribera, J; Juncà, J; González-Pérez, A; Mercadal, S; Guardia, R; Artola, M T; Moreno, M J; Martínez-López, J; Zamora, L; Barba Suñol, Pere; Gil, C; Tormo, M; Cladera, A; Novo, A; Pratcorona, M; Nomdedeu, J; González-Campos, J; Almeida, M; Cervera, J; Montesinos, P; Batlle, M; Vives, S; Esteve, J; Feliu, E; Solé, F; Orfao, A; Ribera, J M. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018 Jul 24
  • Esteve-Arenys, A; Valero, J G; Chamorro-Jorganes, A; Gonzalez, D; Rodriguez, V; Dlouhy, I; Salaverria, I; Campo, E; Colomer, D; Martinez, A; Rymkiewicz, G; Pérez-Galán, P; Lopez-Guillermo, A; Roue, Gael. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018 Abr 01
  • Blanco, Gonzalo; Vardi, Anna; Puiggros, Anna; Gómez-Llonín, Andrea; Muro, Manuel; Rodríguez-Rivera, María; Stalika, Evangelia; Abella, Eugenia; Gimeno, Eva; López-Sánchez, Manuela; Senín, Alicia; Calvo, Xavier; Abrisqueta Costa, Pau; Bosch Albareda, Francesc; Ferrer, Ana; Stamatopoulos, Kostas; Espinet, Blanca. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. Oncoimmunology. 2018 Feb 20
  • Cabezón, Marta; Bargay, Joan; Xicoy, Blanca; García, Olga; Borrás, Josep; Tormo, Mar; Marcé, Sílvia; Pedro, Carme; Valcarcel Ferreiras, David; Jiménez, Maria-José; Guàrdia, Ramón; Palomo, Laura; Brunet, Salut; Vall-Llovera, Ferran; Garcia, Antoni; Feliu, Evarist; Zamora, Lurdes; CETLAM Group. Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 2018 Abr 10
  • Hernández-Boluda, Juan-Carlos; Correa, Juan-Gonzalo; Alvarez-Larrán, Alberto; Ferrer-Marín, Francisca; Raya, José-María; Martínez-López, Joaquín; Velez, Patricia; Pérez-Encinas, Manuel; Estrada, Natalia; García-Gutiérrez, Valentín; Fox, M. Laura; Luño, Elisa; Kerguelen, Ana; Cuevas, Beatriz; Durán, María-Antonia; Ramírez, María-José; Gómez-Casares, Maite; Mata-Vázquez, María-Isabel; Regadera, Anabel; Pereira, Arturo; Cervantes, Francisco; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. British Journal of Haematology. 2018 May 01
  • Goasguen, Jean E; Bennett, John M; Bain, Barbara J; Brunning, Richard; Vallespi Sole, Teresa; Tomonaga, Masao; Zini, Gina; Renault, Alain; (The International Working Group on Morphology of MDS). Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. British Journal of Haematology. 2018 Aug 01
  • Gribben, John G; Bosch Albareda, Francesc; Cymbalista, Florence; Geisler, Christian H; Ghia, Paolo; Hillmen, Peter; Moreno, Carol; Stilgenbauer, Stephan. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology. 2018 Mar 01
  • Kraaijpoel, Noémie; Di Nisio, Marcello; Mulder, Frits I; van Es, Nick; Beyer-Westendorf, Jan; Carrier, Marc; Garcia, David; Grosso, Michael; Kakkar, Ajay K; Mercuri, Michele F; Middeldorp, Saskia; Hernandez, Cristhiam Rojas;Santamaria Ortiz, Amparo; Schwocho, Lee; Segers, Annelise; Verhamme, Peter; Wang, Tzu-Fei; Weitz, Jeffrey I; Zhang, George; Zwicker, Jeffrey I; Büller, Harry R; Raskob, Gary E. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemostasis. 2018 Aug 01
  • Lozano, Ester; Díaz, Tania; Mena, Mari-Pau; Suñe, Guillermo; Calvo, Xavier; Calderón, Marcos; Pérez-Amill, Lorena; Rodríguez, Vanina; Pérez-Galán, Patricia; Roue, Gael; Cibeira, M Teresa; Rosiñol, Laura; Isola, Ignacio; Rodríguez-Lobato, Luis-Gerardo; Martin-Antonio, Beatriz; Bladé, Joan; Fernández de Larrea, Carlos. Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology. 2018 Abr 15
  • Ma, Chun Kei Kris; García-Cadenas, Irene; Fox, M. Laura; Ai, Sylvia; Nivison-Smith, Ian; Milliken, Samuel Thomas; Dodds, Anthony; Fay, Keith; Ma, David D F; Martino, Rodrigo; Sierra, Jorge; Moore, John. Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. Bone Marrow Transplantation. 2018 Nov 01
  • Jiménez-Ubieto, Ana; Grande, Carlos; Caballero, Dolores; Yáñez, Lucrecia; Hernández-Garcia, Miguel Teodoro; Novelli, Silvana; Arranz, Reyes; Ferreiro, José Javier; Bobillo Varelo, Sabela; Mercadal, Santiago; Galeo, Andrea; Jiménez, Javier López; Moraleda, José María; Vallejo, Carlos; Albo, Carmen; Pérez, Elena; Marrero, Carmen; Magnano, Laura; Palomera, Luis; Jarque, Isidro; Martínez-Sánchez, Pilar; Martín, Alejandro; Coria, Erika; López-Guillermo, Armando; Salar, Antonio; Lahuerta, Juan José; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplantation. 2018 Jun 01
  • Barba Suñol, Pere; Martino, R.; Zhou, Q.; Cho, C.; Castro-Malaspina, H.; Devlin, S.; Esquirol, A.; Giralt, S.; Jakubowski, A.A.; Caballero, D.; Maloy, M.; Papadopoulos, E.B.; Piñana, J.L.; Fox, M. Laura; Márquez, F.; Valcarcel Ferreiras, David; Solano, C.; López-Corral, L.; Sierra, J.; Perales, M.-A.. CD34 +  Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age 50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation. 2018 May 01
  • Mestre-Torres, Jaume; Lorenzo-Bosquet, Carles; Cuberas-Borrós, Gemma; Gironella Mesa, Mercedes; Solans-Laque, Roser; Fernández-Codina, Andreu; Bujan-Rivas, Segundo; Castell-Conesa, Joan; Martínez-Valle, Fernando. Utility of the  18 F-Florbetapir positron emission tomography in systemic amyloidosis. Amyloid. 2018 Jun 01
  • Riveiro-Barciela, Mar; Bes, Marta; Quer, Josep; Valcarcel Ferreiras, David; Piriz, Sofia; Gregori, Josep; Llorens, Meritxell; Salcedo, María-Teresa; Piron, Maria; Esteban, Rafael; Buti, Maria; Sauleda, Silvia. Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. Transfusion. 2018 Nov 01
  • Jiménez-Ubieto, Ana; Grande, Carlos; Caballero, Dolores; Yáñez, Lucrecia; Novelli, Silvana; Hernández-Garcia, Miguel Teodoro; Manzanares, María; Arranz, Reyes; Ferreiro, José Javier; Bobillo Varelo, Sabela; Mercadal, Santiago; Galeo, Andrea; Jiménez, Javier López; Moraleda, José María; Vallejo, Carlos; Albo, Carmen; Pérez, Elena; Marrero, Carmen; Magnano, Laura; Palomera, Luis; Jarque, Isidro; Martínez-Sánchez, Pilar; Martín, Alejandro; Coria, Erika; López-Guillermo, Armando; Salar, Antonio; Lahuerta, Juan José; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematological Oncology. 2018 Des 01
  • Martínez-Cuadrón, David; Boluda, Blanca; Martínez, Pilar; Bergua, Juan; Rodríguez-Veiga, Rebeca; Esteve, Jordi; Vives, Susana; Serrano, Josefina; Vidriales, Belen; Salamero Garcia, Olga; Cordón, Lourdes; Sempere, Amparo; Jiménez-Ubieto, Ana; Prieto-Delgado, Julio; Díaz-Beyá, Marina; Garrido, Ana; Benavente, Celina; Pérez-Simón, José Antonio; Moscardó, Federico; Sanz, Miguel A; Montesinos, Pau; CETLAM and PETHEMA groups. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Annals of Hematology. 2018 May 01
  • Montoro Gomez, Julia; Gallur Cuenca, Laura;Merchan Ruiz, Brayan Marcel; Molero, Antonieta; Roldán, Elisa; Martínez-Valle, Ferrán; Villacampa, Guillermo; Navarrete, Mayda; Ortega Blanco, Margarita; Castellví, Josep; Saumell, Silvia; Bobillo Varelo, Sabela; Bosch Albareda, Francesc; Valcarcel Ferreiras, David. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology. 2018 Aug 01
  • Bobillo Varelo, Sabela; Abrisqueta Costa, Pau; Sánchez-González, B; Giné, E; Romero, S; Alcoceba, M; González-Barca, E; González de Villambrosía, S; Sancho, J M; Gomez Pardo, Patricia; Bento, L; Montoro Gomez, Julia; Montes, S; Lopez Hernandez, Andres; Bosch Albareda, Francesc; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperati. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series. Annals of Hematology. 2018 Des 01
  • Hernández-Boluda, Juan-Carlos; Pereira, Arturo; Correa, Juan-Gonzalo; Alvarez-Larrán, Alberto; Ferrer-Marín, Francisca; Raya, José-María; Martínez-López, Joaquín; Velez, Patricia; Pérez-Encinas, Manuel; Estrada, Natalia; García-Gutiérrez, Valentín; Fox, M. Laura; Payer, Angel; Kerguelen, Ana; Cuevas, Beatriz; Durán, María-Antonia; Ramírez, María-José; Gómez-Casares, María-Teresa; Mata-Vázquez, María-Isabel; Mora, Elvira; Gómez, Montse; Cervantes, Francisco. Prognostic risk models for transplant decision-making in myelofibrosis. Annals of Hematology. 2018 May 01
  • Colonna, Paolo; von Heymann, Christian; Santamaria Ortiz, Amparo; Matsushita, Yasuyuki; Unverdorben, Martin. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design. Clin Cardiol. 2018 Sep 01
  • Body, Simon; Esteve-Arenys, Anna; Recasens-Zorzo, Clara; Troussard, Xavier; Roue, Gael; Sola, Brigitte. A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor ß agonists toward tumor burden. Leukemia & Lymphoma. 2018 Jul 01
  • Guillem, Vicent; Calabuig, Marisa; Brunet, Salut; Esteve, Jordi; Escoda, Lourdes; Gallardo, David; Ribera, Josep-Maria; Queipo de Llano, María Paz; Arnan, Montserrat; Pedro, Carme; Amigo, María Luz; Martí-Tutusaus, Josep M; García-Guiñón, Antoni; Bargay, Joan; Sampol, Antonia; Salamero Garcia, Olga; Font, Llorenç; Talarn, Carme; Hoyos, Montserrat; Díaz-Beyá, Marina; Garrido, Ana; Navarro, Blanca; Nomdédeu, Josep; Sierra, Jordi; Tormo, Mar. Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. Leukemia & Lymphoma. 2018 Oct 01
  • González-Gascón Y Marín, Isabel; Hernández-Sanchez, María; Rodríguez-Vicente, Ana Eugenia; Puiggros, Anna; Collado, Rosa; Luño, Elisa; González, Teresa; Ruiz-Xivillé, Neus; Ortega Blanco, Margarita; Gimeno, Eva; Muñoz, Carolina; Infante, Maria Stefania; Delgado, Julio; Vargas, María Teresa; González, Marcos; Bosch Albareda, Francesc; Espinet, Blanca; Hernández-Rivas, Jesús María; Hernández, José Ángel; Grupo Español de Leucemia Linfática Crónica (GELLC) and Grupo Cooperativo Españo. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2018 Mar 01
  • Ribera, Josep-Maria; Morgades, Mireia; Montesinos, Pau; Martino, Rodrigo; Barba Suñol, Pere; Soria, Beatriz; Bermúdez, Arancha; Moreno, María-José; González-Campos, José; Vives, Susana; Gil, Cristina; Abella, Eugenia; Guàrdia, Ramon; Martínez-Carballeira, Daniel; Martínez-Sánchez, Pilar; Amigo, María-Luz; Mercadal, Santiago; Serrano, Alfons; López-Martínez, Aurelio; Vall-Llovera, Ferran; Sánchez-Sánchez, María-José; Peñarrubia, María-Jesús; Calbacho, María; Méndez, Jose-Angel; Bergua, Juan; Cladera, Antonia; Tormo, Mar; García-Belmonte, Daniel; Feliu, Evarist; Ciudad, Juana; Orfao, Alberto; Valcarcel Ferreiras, David. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia & Lymphoma. 2018 Jul 01
  • Sole, Carla; Martinez, Daniel; Gine, Eva; Gonzalez-Farre, Blanca; Perez-Galan, Patricia; Roncador, Giovanna; Campo, Elias; Matutes, Estela; Lopez-Guillermo, Armando; Roue, Gael; Martinez, Antonio. Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2018 Jan 01
  • Motlló, Cristina; Ribera, Josep-Maria; Morgades, Mireia; Granada, Isabel; Montesinos, Pau; Mercadal, Santiago; González-Campos, José; Moreno, María-José; Barba Suñol, Pere; Cervera, Marta; Barrios, Manuel; Novo, Andrés; Bernal, Teresa; Hernández-Rivas, Jesús-María; Abella, Eugenia; Amigo, María-Luz; Tormo, Mar; Martino, Rodrigo; Lavilla, Esperanza; Bergua, Juan; Serrano, Alfons; García-Belmonte, Daniel; Guàrdia, Ramon; Grau, Javier; Feliu, Evarist; PETHEMA Group, Spanish Society of Hematology. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leukemia & Lymphoma. 2018 Jan 01
  • Baptista, Maria Joao; Tapia, Gustavo; Morgades, Mireia; Muncunill, Josep; Muñoz-Marmol, Ana-María; Montoto, Silvia; Gribben, John G; Calaminici, Maria; Martinez, Antonio; Gonzalez-Farre, Blanca; Dlouhy, Ivan; González-Barca, Eva; Terol, María-José; Miralles, Pilar; Alcoceba, Miguel; Vall-Llovera, Ferran; Briones, Javier; Abrisqueta Costa, Pau; Abella, Eugenia; Provencio, Mariano; García-Ballesteros, Carlos; Moraleda, José-María; Sancho, Juan-Manuel; Ribera, Josep-Maria; Mate, José-Luis; Navarro, José-Tomas. Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2018 Oct 15 (Epub ahead of print)
  • Bosch-Vilaseca, Anna; García-Cadenas, Irene; Roldán, Elisa; Novelli, Silvana; Barba Suñol, Pere; Esquirol, Albert; Valcarcel Ferreiras, David; Martino, Rodrigo; Sierra, Jorge. Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. European Journal of Haematology. 2018 Sep 01
  • Larrainzar-Coghen, Thais; Rodríguez-Pardo, Dolors; Barba Suñol, Pere; Aguilar Company, Juan; Rodríguez, Virginia; Roig, Gloria; Ferrer, Carmen; Ruiz-Camps, Isabel; Almirante, Benito. Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study. European Journal of Clinical Microbiology & Infectious Diseases. 2018 Nov 01
  • Orti, Guillermo; Sanz, Jaime; García-Cadenas, Irene; Sánchez-Ortega, Isabel; Alonso, Laura; Jiménez, Maria José; Sisinni, Luisa; Azqueta, Carmen; Salamero Garcia, Olga; Badell, Isabel; Ferra, Christelle; de Heredia, Cristina Diaz; Parody, Rocio; Sanz, Miguel Angel; Sierra, Jorge; Piñana, Jose Luis; Querol, Sergi; Valcarcel Ferreiras, David. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology. 2018 Jun 01
  • Yeung, Cecilia Cs; Hockenbery, David M; Westerhoff, Maria; Coutre, Steven E; Sedlak, Ruth H; Dubowy, Ronald L; Munugalavadla, Veerendra; Taylor, Kerry; Bosch Albareda, Francesc. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. Future Oncology. 2018 Sep 01
  • Piedra-Carrasco, Nuria; Miguel, Lucia; Fàbrega, Anna; Viñado, Belén; Campany, David; Mir, Alba; Fox, M. Laura; Almirante, Benito; Larrosa, Nieves; Ruiz-Camps, Isabel; González-López, Juan José. Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient. Microbial Drug Resistance. 2018 Mar 01
  • Ribera, Josep-Maria; García, Olga; Gil, Cristina; Mercadal, Santiago; García-Cadenas, Irene; Montesinos, Pau; Barba Suñol, Pere; Vives, Susana; González-Campos, José; Tormo, Mar; Esteve, Jordi; Lopez Hernandez, Andres; Moreno, María José; Ribera, Jordi; Alonso, Natalia; Bermúdez, Arancha; Amigo, María Luz; Genescà, Eulàlia; García, Daniel; Vall-Llovera, Ferran; Bergua, Juan Miguel; Guàrdia, Ramon; Monteserín, María Carmen; Bernal, Teresa; Calbacho, María; Martínez, María Pilar; Feliu, Evarist; Valcarcel Ferreiras, David. Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia Research. 2018 May 01
  • Miyazaki, Yasushi; Tuechler, Heinz; Sanz, Guillermo; Schanz, Julie; Garcia-Manero, Guillermo; Solé, Francesc; Bennett, John M; Bowen, David; Fenaux, Pierre; Dreyfus, Francois; Kantarjian, Hagop; Kuendgen, Andrea; Malcovati, Luca; Cazzola, Mario; Cermak, Jaroslav; Fonatsch, Christa; Le Beau, Michelle M; Slovak, Marilyn L; Santini, Valeria; Lübbert, Michael; Maciejewski, Jaroslaw; Machherndl-Spandl, Sigrid; Magalhaes, Silvia M M; Pfeilstöcker, Michael; Sekeres, Mikkael A; Sperr, Wolfgang R; Stauder, Reinhard; Tauro, Sudhir; Valent, Peter; Vallespi Sole, Teresa; van de Loosdrecht, Arjan A; Germing, Ulrich; Haase, Detlef; Greenberg, Peter L. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research. 2018 Oct 01
  • Xicoy, Blanca; Triguero, Ana; Such, Esperanza; García, Olga; Jiménez, María-José; Arnán, Montserrat; Bernal, Teresa; Diaz-Beya, Marina; Valcarcel Ferreiras, David; Pedro, Carme; Ramos, Fernando; Amigo, María-Luz; Collado, Rosa; Palomo, Laura; Ardanaz, María-Teresa; Cedena, María-Teresa; Grau, Javier; Zamora, Lurdes; Sanz, Guillermo. The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. Leukemia Research. 2018 May 09
  • Mohty, Mohamad; Terpos, Evangelos; Mateos, Maria-Victoria; Cavo, Michele; Lejniece, Sandra; Beksac, Meral; Bekadja, Mohamed Amine; Legiec, Wojciech; Dimopoulos, Meletios; Stankovic, Svetlana; Durán, Maria Soledad; De Stefano, Valerio; Corso, Alessandro; Kochkareva, Yulia; Laane, Edward; Berthou, Christian; Salwender, Hans; Masliak, Zvenyslava; Peceliunas, Valdas; Willenbacher, Wolfgang; Silva, João; Louw, Vernon; Nemet, Damir; Borbényi, Zita; Abadi, Uri; Pedersen, Robert Schou; Cernelc, Peter; Potamianou, Anna; Couturier, Catherine; Feys, Caroline; Thoret-Bauchet, Florence; Boccadoro, Mario; EMMOS Investigators; Bekadja, Mohamed; Hamladji, Rose-Marie; Ali, Hocine Ait; Hamdi, Selma; Touhami, Hadj; Mansour, Nourredine Sidi; Willenbacher, Wolfgang; Linkesch, Werner; Nemet, Damir; Pedersen, Robert Shou; Abildgaard, Niels; Laane, Edward; Hein, Marju; Mohty, Mohamad; Eveillard, Jean Richard; Yamani, Abderrazak El; Moreau, Philippe; Sanhes, Laurence; Lepeu, Gérard; Laribi, Kamel; Jourdan, Eric; Fitoussi, Olivier; Allangba, Olivier; Fleury, Joël; Escoffre, Martine; Benramdane, Riad; Cartron, Guillaume; Dine, Gérard; Legouffe, Eric; Harich, Hanns-Detlev; Illmer, Thomas; Dörfel, Steffen; Hannig, Carla Verena; Koenigsmann, Michael; Prange-Krex, Gabriele; Salwender, Hans; Tamm, Ingo; Zeller, Wolfgang; Maasberg, Michael; Schlag, Rudolf; Klausmann, Martine; Uhlig, Jens; Alkemper, Burkhard; Schütz, Stefan; Tessen, Hans-Werner; Mohr, Benno; Schmidt, Peter; Heinrich, Bernhard; Hebart, Holger; Seipelt, Gernot; Zoeller, Thomas; Heits, Frank; Müller-Naendrup, Clemens; Hansen, Richard; Repp, Roland; Von Weikersthal, Ludwig Fischer; Schmits, Rudolf; Heßling, Jörg; Krammer-Steiner, B; Janzen, Viktor; Schauer, Michael; Grüner, Marcus W; Kisro, Jens; Denzlinger, Claudio; Freier, Werner; Junghanss, Christian; Görner, Martin; Laichinger, Katharina; Ostermann, Helmut; Dürk, Heinz; Hess, Georg; Reich, Gernot; Terpos, Evangelos; Dimopoulos, Meletios; Matsouka, Panagiota; Pouli, Anastasia; Anagnostopoulos, Achilles; Masszi, Tamas; Borbényi, Zita; Ivanyi, Janos; Szomor, Arpad; Abadi, Uri; Nagler, Arnon; Magen, Hila; Avivi, Irit; Quitt, Miriam; Palumbo, Antonio; Boccadoro, Mario; De Stefano, Valerio; Za, Tommaso; Vallisa, Daniele; Foa, Roberto; Corso, Alessandro; Bosi, Alberto; Vacca, Angelo; Lanza, Francesco; Palazzo, Giulia; Avvisati, Giuseppe; Cavo, Michele; Ferrara, Felicetto; Consoli, Ugo; Cantonetti, Maria; Angelucci, Emanuele; Califano, Catello; Di Raimondo, Francesco; Guarini, Attilio; Musso, Maurizio; Pizzuti, Michele; Giuliani, Nicola; Ardizzoia, Antonio; Di Renzo, Nicola; Gaidano, Gianluca; Gozzetti, Alessandro; Pitini, Vincenzo; Farina, Gabriella; Centurioni, Riccardo; De Fabritiis, Paolo; Iuliano, Francesco; La Nasa, Giorgio; La Verde, Giacinto; Pane, Fabrizio; Recine, Umberto; La Targia, Maria; Mineo, Giuseppe; Cangialosi, Clotilde; Fagnani, Daniele; Federici, Augusto; Romano, Atelda; Specchia, Giorgina; Storti, Sergio; Bongarzoni, Velia; Bacigalupo, Andrea; Gobbi, Marco; Latte, Giancarlo; Mannina, Donato; Capalbo, Silvana; Lejniece, Sandra; Peceliunas, Valdas; Jurgutis, Mindaugas; Stankovic, Svetlana; Legiec, Wojciech; Woszczyk, Dariusz; Holojda, Jadwiga; Gornik, Slawomir; Pluta, Andrzej; Morawiec-Szymonik, Elzbieta; Kyrcz-Krzemien, Slawomira; Homenda, Wojciech; Grosicki, Sebastian; Sulek, Kazimierz; Lange, Andrzej; Kloczko, Janusz; Starzak-Gwozdz, Jolanta; Hellmann, Andrzej; Komarnicki, Mieczyslaw; Kuliczkowski, Kazimierz; Viveiros, Carolina; Gonçalves, Cristina; Esefyeva, Natalia; Kochkareva, Julia; Kaplanov, Kamil; Volodicheva, Elena; Laricheva, Elena; Dergacheva, Valentina; Chukavina, Marina; Volchenko, Natalia; Nazarova, Irina; Anchukova, Ludmila; Ovanesova, Elena; Gritsenko, Taras; Salogub, Galina; Magomedova, Ludmila; Kuznetsova, Irina; Osyunikhina, Svetlana; Serdyuk, Olga; Karyagina, Elena; Ivanova, Valentina; Cernelc, Slovenia Peter; Louw, Vernon; Coetzee, Corlia; Gunther, Karen; Moodley, Dhayanithi; Duran, Soledad; Gutiérrez, Asunción Echeveste; De Oteyza, Jaime Perez; Capote, Francisco Javier; Casanova, Maria; Sanchez, Jesus Martin; Rios-Herranz, Eduardo; Ibañez-Garcia, Jeronima; Herranz, Maria Jose; Hernandez, Belen; Sanchez, Sara Sanchez; Escalante, Fernando; Carnicero, Fernando; Lleonart, Joan Bargay; Gironella Mesa, Mercedes; Martínez, Rafael; De La Guia, Ana Lopez; Palomera, Luis; Iglesias, Rebeca; Ramos, Fernando Solano; De La Serna, Javier; Sanchez, Pedro Garcia; Vidal, Juan Besalduch; Mateos, Maria-Victoria; Morfa, Miguel Diaz; Beksac, Turkey-Meral; Vural, Filiz; Aydin, Yildiz; Unal, Ali; Goker, Hakan; Bilgir, Oktay; Guvenc, Birol; Turgut, Mehmet; Ozet, Gulsum Gulistan; Ali, Ridvan; Masliak, Zvenyslava; Kyselyova, Maryna; Glushko, Nataliia; Vybyrana, Renata; Skrypnyk, Igor; Tretyak, Natalya; Kharchevska, Tetiana; Dyagil, Iryna; Popovs’ka, Tetiana; Shimanskiy, Vadim; Lysa, Tamila; Oliynyk, Hanna; Vilchevskaya, Kateryna; Kryachok, Iryna; Popovych, Yuriy; Romanyuk, Natalia; Yushchenko, Natalia; Kaplan, Polina; Rekhtman, Grygoriy; Pylypenko, Halyna; Kozlov, Viktor; Mohty, Mohamad; Terpos, Evangelos; Mateos, Maria-Victoria; Palumbo, Antonio; Drach, Johannes; Boccadoro, Mario; Harousseau, Jean-Luc; Einsele, Hermann; Goldschmidt, Hartmut; Facon, Thierry; Michalet, Mauricette; Savchenko, Valery G; De la Rubia, Javier; Cook, Gordon; Mellqvist, Ulf-Henrik; Ludwig, Heinz. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma Leukemia. 2018 Oct 01
  • Rosillo, Claudia; Avila, Ana Maria; Huang, Yao-Ting; Devlin, Sean; Cho, Christina; Montoro Gomez, Julia; Maloy, Molly A; Papanicolaou, Genovefa A; Barba Suñol, Pere; Perales, Miguel-Angel. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 20418 Aug 01
  • Giraldo, Pilar; Andrade-Campos, Marcio; Alfonso, Pilar; Irun, Pilar; Atutxa, Koldo; Acedo, Antonio; Barez, Abelardo; Blanes, Margarita; Diaz-Morant, Vicente; Fernández-Galán, Ma Angeles; Franco, Rafael; Gil-Cortes, Cristina; Giner, Vicente; Ibañez, Angela; Latre, Paz; Loyola, Ines; Luño, Elisa; Hernández-Martin, Roberto; Medrano-Engay, Blanca; Puerta, José; Roig, Inmaculada; de la Serna, Javier; Salamero Garcia, Olga; Villalón, Lucia; Pocovi, Miguel. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. Blood Cell Mol Dis. 2018 Feb 01
  • Olivera, Pavel; Gabilondo, Miren; Constans, Mireia; Tàssies, Dolors; Plensa, Esther; Pons Escoll, Veronica; Las Heras, Germán; Jiménez, Carmen; Campoy, Desirée; Bustins, Anna; Oliver, Artur; Marzo, Cristina; Canals, Tania; Varela, Anna; Sorigue, Marc; Sánchez, Eva; Ene, Gabriela; Perea, Granada; Vicente, Laura; López, Meritxell; Cerdá, María; Johansson, Erik; Aguinaco, M Reyes; Santos, Nazly; Mateo, José; Reverter, Joan Carles; Moya, Ángel; Santamaria Ortiz, Amparo. Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. Medicina Clinica. 2018 Sep 14
  • Beneitez, D. Use of intravenous iron in the current clinical practice. Medicina Clinica. 2018 Mar 09
  • Chong, Lauren C; Ben-Neriah, Susana; Slack, Graham W; Freeman, Ciara; Ennishi, Daisuke; Mottok, Anja; Collinge, Brett; Abrisqueta Costa, Pau; Farinha, Pedro; Boyle, Merrill; Meissner, Barbara; Kridel, Robert; Gerrie, Alina S; Villa, Diego; Savage, Kerry J; Sehn, Laurie H; Siebert, Reiner; Morin, Ryan D; Gascoyne, Randy D; Marra, Marco A; Connors, Joseph M; Mungall, Andrew J; Steidl, Christian; Scott, David W. High-resolution architecture and partner genes of  MYC  rearrangements in lymphoma with DLBCL morphology. Blood Advances. 2018 Oct 23
  • New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Scott DW; Abrisqueta P; Wright GW; Slack GW; Mottok A; Villa D; Jares P; Rauert-Wunderlich H; Royo C; Clot G; Pinyol M; Boyle M; Chan FC; Braziel RM; Chan WC; Weisenburger DD; Cook JR; Greiner TC; Fu K; Ott G; Delabie J; Smeland EB; Holte H; Jaffe ES; Steidl C; Connors JM; Gascoyne RD; Rosenwald A; Staudt LM; Campo E; Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project. 2017. J Clin Oncol.35: 1668-1677.
  • Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. Vitolo U; Trnený M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH. 2017.J Clin Oncol.35: 3529-3537.
  • Observation as the initial management strategy in patients with mantle cell lymphoma. Abrisqueta P; Scott DW; Slack GW; Steidl C; Mottok A; Gascoyne RD; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D. 2017.Ann Oncol.28: 2489-2495.
  • A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG. 2017.Leukemia.31: 2799-2806.
  • Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas. 2017.HAEMATOLOGICA.102: 103-109.
  • The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF. 2017.HAEMATOLOGICA.102: 1776-1784.
  • The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κBmutational status. Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P. 2017.HAEMATOLOGICA.
  • Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M. 2017.LANCET HAEMATOL.4: 475-486.
  • Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Aguilar-Guisado M; Espigado I; Martín-Peña A; Gudiol C; Royo-Cebrecos C; Falantes J; Vázquez-López L; Montero MI; Rosso-Fernández C; de la Luz Martino M; Parody R; González-Campos J; Garzón-López S; Calderón-Cabrera C; Barba P; Rodríguez N; Rovira M; Montero-Mateos E; Carratalá J; Pérez-Simón JA; Cisneros JM. 2017.LANCET HAEMATOL.
  • Excess mortality in the myelodysplastic syndromes.Nomdedeu M; Pereira A; Ramos F; Valcárcel D; Costa D; Arnan M; Calvo X; Pomares H; Luño E; Díaz-Campelo M; Collado R; de Paz R; Falantes JF; Pedro C; Marco J; Oirtzabal I; Sánchez-García J; Tormo M; Cedena MT; Nomdedeu B; Sanz G; Spanish MDS Group. 2017.AM J HEMATOL.92: 149-154.
  • Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L. 2017.AM J HEMATOL.92: 614-621.
  • Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F. 2017.Oncotarget.8: 742-756.
  • Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Puiggros, Anna; Collado, Rosa; Jose Calasanz, Maria; Ortega, Margarita; Ruiz-Xiville, Neus; Rivas-Delgado, Alfredo; Luno, Elisa; Gonzalez, Teresa; Navarro, Blanca; Garcia-Malo, MaDolores; Valiente, Alberto; Angel Hernandez, Jose; Teresa Ardanaz, Maria; Angeles Pinan, Maria; Laura Blanco, Maria; Hernandez-Sanchez, Maria; Batlle-Lopez, Ana; Salgado, Rocio; Salido, Marta; Ferrer, Ana; Abrisqueta, Pau; Gimeno, Eva; Abella, Eugenia; Ferra, Christelle; Jose Terol, Maria; Ortuno, Francisco; Costa, Dolors; Moreno, Carol; Carbonell, Felix; Bosch, Francesc; Delgado, Julio; Espinet, Blanca. 2017.Oncotarget.8: 54297-54303.
  • Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34(+) Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MR; Young JW; O’Reilly RJ; Giralt SA; Perales MA. 2017.Biol Blood Marrow Transplant.23: 67-74.
  • Ex Vivo CD34(+)-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic. Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O’Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM. 2017.Biol Blood Marrow Transplant.23: 452-458.
  • Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. Castillo N; García-Cadenas I; Barba P; Canals C; Díaz-Heredia C; Martino R; Ferrà C; Badell I; Elorza I; Sierra J; Valcárcel D; Querol S.2017.Biol Blood Marrow Transplant.23: 491-497.
  • Do Patients and Physicians Agree When They Assess Quality of Life? Barata A; Martino R; Gich I; García-Cadenas I; Abella E; Barba P; Briones J; Brunet S; Esquirol A; García-Pallarols F; Garrido A; Granell M; Martinez J; Mensa I; Novelli S; Sanchez-Blanco B; Valcárcel D; Sierra J. 2017.Biol Blood Marrow Transplant.23: 1005-1010.
  • Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Gerds AT; Woo Ahn K; Hu ZH; Abdel-Azim H; Akpek G; Aljurf M; Ballen KK; Beitinjaneh A; Bacher U; Cahn JY; Chhabra S; Cutler C; Daly A; DeFilipp Z; Gale RP; Gergis U; Grunwald MR; Hale GA; Hamilton BK; Jagasia M; Kamble RT; Kindwall-Keller T; Nishihori T; Olsson RF; Ramanathan M; Saad AA; Solh M; Ustun C; Valcárcel D; Warlick E; Wirk BM; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W. 2017.Biol Blood Marrow Transplant.23: 971-979.
  • A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R. 2017.Biol Blood Marrow Transplant.23: 1177-1185.
  • Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ. 2017.Biol Blood Marrow Transplant.23: 1631-1640.
  • Efficacy of ß-Lactam/ß-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J; BICAR Study Group. 2017.Antimicrob Agents Chemother.
  • Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Carabia J; Carpio C; Abrisqueta P; Jiménez I; Purroy N; Calpe E; Palacio C; Bosch F; Crespo M. 2017.Sci Rep.7: 12262-0.
  • Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells. Body S; Esteve-Arenys A; Miloudi H; Recasens-Zorzo C; Tchakarska G; Moros A; Bustany S; Vidal-Crespo A; Rodriguez V; Lavigne R; Com E; Casanova I; Mangues R; Weigert O; Sanjuan-Pla A; Menéndez P; Marcq B; Picquenot JM; Pérez-Galán P; Jardin F; Roué G; Sola B. 2017.Sci Rep.7: 13946-0.
  • Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. García-Cadenas I; Rivera I; Martino R; Esquirol A; Barba P; Novelli S; Orti G; Briones J; Brunet S; Valcarcel D; Sierra J. 2017.Bone Marrow Transplant.52: 107-113.
  • Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA. 2017.Bone Marrow Transplant.52: 438-444.
  • Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O’Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA. 2017.Bone Marrow Transplant.52: 1629-1636.
  • An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase..Steegmann JL; Colomer D; Gómez-Casares MT; García-Gutiérrez V; Ortí G; Ramírez-Payer A; Olavarria E; Vall-Llovera F; Giraldo P; Conde E; Vallansot R; López-Lorenzo JL; Palomera L; Álvarez-Larrán A; Conesa V; Bautista G; Casas L; Giles F; Hochhaus A; Casado-Montero LF. 2017.J Cancer Res Clin Oncol.143: 2059-2066.
  • Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galego A; Jiménez JL; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Coria E; Rodriguez A; Martín A; López-Guillermo A; Salar A; Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu.2017.Cancer Med.6: 2766-2774.
  • Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. Montoro J; Robledo C; Zamora L; Valcárcel D; Ramos F. 2017.ANN HEMATOL.96: 317-318.
  • Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. de Swart L; Smith A; MacKenzie M; Symeonidis A; Neukirchen J; Mikulenková D; Vallespí T; Zini G; Paszkowska-Kowalewska M; Kruger A; Saft L; Fenaux P; Bowen D; Hellström-Lindberg E; Cermák J; Stauder R; Tatic A; Holm MS; Malcovati L; Madry K; Droste J; Blijlevens N; de Witte T; Germing U. 2017.ANN HEMATOL.96: 1105-1112.
  • Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J. 2017.ANN HEMATOL.96: 1069-1075.
  • Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study. Sáez-Giménez B; Berastegui C; Sintes H; Perez-Miranda J; Figueredo A; López Meseguer M; Monforte V; Bravo C; Santamaría A; Ramon MA; Gómez-Ollés S; Roman A. 2017.TRANSPL INT.30: 1266-1274.
  • Further psychometric validation of the GAH scale: Responsiveness and effect size. Cruz-Jentoft AJ; González B; de la Rubia J; Hernández Rivas JÁ; Soler JA; Fernández Lago C; Arnao M; Gironella M; Pérez Persona E; Zudaire MT; Olivier C; Altés A; García Guiñón A; Nomdedeu B; Arnan M; Ramírez Payer Á; Sánchez-Godoy P; Pajuelo N; Vilanova D; Monjil DF; Bonanad S; GAH Group. 2017.J GERIATR ONCOL.8: 211-215.
  • Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D. 2017.EXP HEMATOL.48: 1-11.
  • Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E; PETHEMA Group, Spanish Society of Hematology.2017.Leuk Lymphoma.58: 145-152.
  • Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Hernández-Boluda JC; Correa JG; García-Delgado R; Martínez-López J; Alvarez-Larrán A; Fox ML; García-Gutiérrez V; Pérez-Encinas M; Ferrer-Marín F; Mata-Vázquez MI; Raya JM; Estrada N; García S; Kerguelen A; Durán MA; Albors M; Cervantes F. 2017.EUR J HAEMATOL.98: 407-414.
  • Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions..de Sevilla MF; Català A; Rives S; Berrueco R; Vidiella N; Camós M; Torrebadell M; Alonso-Saladrigues A; Mesegué M; Ruiz-Llobet A; Blanco-Álvarez A; Benéitez D. 2017.PEDIATR BLOOD CANCER.
  • Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group..Nomdedeu M; Pereira A; Calvo X; Colomer J; Sole F; Arias A; Gomez C; Luño E; Cervera J; Arnan M; Pomares H; Ramos F; Oiartzabal I; Espinet B; Pedro C; Arrizabalaga B; Blanco ML; Tormo M; Hernandez-Rivas JM; Díez-Campelo M; Ortega M; Valcárcel D; Cedena MT; Collado R; Grau J; Granada I; Sanz G; Campo E; Esteve J; Costa D; Spanish MDS Group. 2017.Leuk Res.63: 85-89.
  • Clinical efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum ß-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J; BICAR study group. 2017.BMJ OPEN.
  • Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Hidalgo M; Álvarez R; Gallego J; Guillén-Ponce C; Laquente B; Macarulla T; Muñoz A; Salgado M; Vera R; Adeva J; Alés I; Arévalo S; Blázquez J; Calsina A; Carmona A; de Madaria E; Díaz R; Díez L; Fernández T; de Paredes BG; Gallardo ME; González I; Hernando O; Jiménez P; López A; López C; López-Ríos F; Martín E; Martínez J; Martínez A; Montans J; Pazo R; Plaza JC; Peiró I; Reina JJ; Sanjuanbenito A; Yaya R; Carrato A. 2017.Clin Transl Oncol.19: 667-681.
  • Asparaginase use for the treatment of acute lymphoblastic leukemia..Barba P; Dapena JL; Montesinos P; Rives S. 2017.Med Clin (Barc).148: 225-231.
  • Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC). 2017.Med Clin (Barc).148: 3811-3819.
  • Bridge therapy in patients under anticoagulation: Is it still the question? Santamaría A. 2017.Med Clin (Barc).149: 303-304.
  • Analytical parameters and vital signs in patients subjected to dental extraction. Jané-Pallí E; Arranz-Obispo C; González-Navarro B; Murat J; Ayuso-Montero R; Rojas S; Santamaría A; Jané-Salas E; López-López J. 2017.J Clin Exp Dent.
  • Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Sanz J; Kwon M; Bautista G; Sanz MA; Balsalobre P; Piñana JL; Solano C; Duarte R; Ferrá C; Lorenzo I; Martín C; Barba P; Pascual MJ; Martino R; Gayoso J; Buño I; Regidor C; de la Iglesia A; Montoro J; Díez-Martín JL; Sanz GF; Cabrera R. 2017.Blood Adv.1: 1047-1055.
  • Noelia Purroy; Júlia Carabia; Pau Abrisqueta; Leire Egia; Meritxell Aguiló; Cecilia Carpio; Carles Palacio; Marta Crespo; Francesc Bosch. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017 Jan 3;8(1):742-756
  • Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D. Donor Lymphocyte Infusions in AML and MDS:enhancing the Graft-versus-Leukemia effect. Experimental Hematology. 24/12/2016.  [Epub ahead of print]
  • Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; tamatopoulos K; Espinet B. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016 Dec 6;7(49):80916-80924
  • Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic LymphocyticLeukemia. Advanced Therapies. 33(10), pp. 1814 – 1830. 03/10/2016.
  • González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Sanzo C; Aventín A; Puiggros A; Collado R; Heras C; Muñoz C; Delgado J; Ortega M; González MT; Marugán I; de la Fuente I; Recio I; Bosch F; Espinet B; González M; Hernández-Rivas JM; Hernández JÁ;; On behalf of Grupo Español de Leucemia Linfática Crónica (GELLC); Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016 Jun;34(2):84-92
  • Bär C; Povedano JM; Serrano R; Benitez-Buelga C; Popkes M; Formentini I; Bobadilla M; Bosch F; Blasco MA. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 127 – 14, pp. 1770 – 1779. 07/04/2016.
  • Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O’Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; , Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An European research initiative on CLL (ERIC) study. Leukemia. 2016 Apr;30(4):929-36.
  • Pons V; Olivera P; García-Consuegra R,; López-Andreoni L; Martín-Begué N; García A, Hidalgo J,; Bosch F; Santamaría A. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. J Thromb Thrombolysis. 2016 Apr;41(3):544-7
  • Hernández JÁ; Hernández-Sánchez M; Rodríguez-Vicente AE; Grossmann V; Collado R; Heras C; Puiggros A; Martín AÁ; Puig N; Benito R; Robledo C; Delgado J; González T; Queizán JA; Galende J; de la Fuente I; Martín-Núñez G; Alonso JM; Abrisqueta P; Luño E; Marugán I; González-Gascón I; Bosch F; Kohlmann A; González M; Espinet B; Hernández-Rivas JM. A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS One. 2015 Dec 2;10(11):e0143073.
  • Riveiro-Barciela M; Artaza G; Abrisqueta P; Bosch F; Buti M. Importance of hepatitis B virus screening in hematological patients. Gastroenterol Hepatol. 2015 Nov;38(9):563-4
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Palacio C; Bosch F; Crespo M. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015 Apr 10;6(10):7632-43.
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.
  • Maria Joao Baptista; Eva Calpe; Eva Fernández; Lluis Colomo; Teresa Marta Cardesa-Salzmann; Pau Abrisqueta; Francesc Bosch; Marta Crespo. Analysis of the IGHV region in Burkitt’s lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leuk Res. 2014 Apr;38(4):509-15
  • Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72
  • Abrisqueta P; Villamor M; Terol MJ; González- Barca E; Ferrà C; Abella E; Delgado J; Garcia-Marco JA; Gonzalez Y; CarbonellF; Monzo E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9.05/12/2013.
  • Calpe E; Purroy N; Carpio C; Abrisqueta P; Carabia J; Palacio C; Castellví J; Crespo M; Bosch F.ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation. PLoS One. 2013 Dec 3;8(12):e81221.
  • Puiggros A; DelgadoJ; Rodriguez- Vicente A; Collado R; Aventín A; Luño E; Luño E; Grau J; Hernandez JÁ; Marugán I; Ardanaz M; González T; Valiente A; Osma M; Calasanz MJ; Sanzo C; Carrió A; Ortega M; Santacruz R; Abrisqueta P; Abella E; Bosch F; Carbonell F; Solé F; Hernández JM; Espinet B. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. Br J Haematol. 2013 Oct;163(1):47-54
  • Mora D; Barba P; Castillo N; Aizpurua M; Rosellé E; Bosch F; Valcárcel D. Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report. Transpl Infect Dis. 2013 Jun;15(3):E107-10
  • Villamor N; Conde L; Martínez-Trillos A; Cazorla M; Navarro A; Beà S; López C; Colomer D; Pinyol M; Aymerich, M; Rozman M; Abrisqueta P; Baumann T; Delgado J; Giné E; González-Díaz M; Hernández JM; Colado E; Payer AR; Rayon C; Navarro B; José Terol M; Bosch F; Quesada V; Puente XS; López-Otín C; Jares P; Pereira A; Campo E; López-Guillermo A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013 Abr; 27(5): 1100 – 1106.
  • Baptista MJ, Muntanola A, Calpe E, Abrisqueta P, Salamero O, Fernandez E, Codony C, Gine E, Kalko SG, Crespo M, Bosch F. Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clin Cancer Res. 2012 Sep;18(21):5924-33.
  • Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymph. 2012 Mar;53(3):417-23.
  • Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
  • Calpe E, Codony C, Baptista MJ, Abrisqueta P, Del Carpio C, Purroy N, Bosch F, Crespo M. ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011 Oct 20; 111(16): 4401-10- 2011.
  • Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, Marcos MÁ, Martínez MJ, Tudó G, Bosch F, Pahissa A, de Anta MT, Pumarola T. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis. 2010 Nov;68(3):214-9.
  • M Hallek*, K Fischer*, G Fingerle-Rowson, A M Fink, R Busch, J Mayer, M Hensel, G Hopfi nger, G Hess, U von Grünhagen, M Bergmann, J Catalano, P L Zinzani, F Caligaris-Cappio, J F Seymour, A Berrebi, U Jäger, B Cazin, M Trneny, A Westermann, C M Wendtner, B F Eichhorst, P Staib, A Bühler, D Winkler, T Zenz, S Böttcher, M Ritgen, M Mendila, M Kneba, H Döhner, S Stilgenbauer, International Group of investigators; German Chronic Lymphocityc Study Group, Collaborators: Hillmen P, Dighiero G, Bosch F, Brugiatelli M, Pigeot I. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74.
  • Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010 Sep; 95(9):1526-33.
  • Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.  Leuk Lymph. 2010 Jul;51(7):1225-32
  • Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M,Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol. 2010 Jun;21(6):1211-6.
  • Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E. Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Res. 2010 Feb 15; 70(4):1408-18
  • Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
  • Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A,Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009 Sep 3;114(10):2044-50
  • Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. J Clin Oncol. 2008 Oct 20;26(30):4966-72.
  • Enjuanes A, Benavente Y, Bosch F, Martín-Guerrero I, Colomer D, Pérez-Alvarez S, Reina O, Ardanaz MT, Jares P, García-Orad A, Pujana MA, Montserrat E, de Sanjosé S, Campo E. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008 Dec 15;68(24):10178-86.
  • Giné E, Crespo M, Muntañola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica. 2008 Jan; 93(1):75-82.
  • Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica. 2008 Jan; 93(1):132-6.
  • Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1; 14(1):155-61.
  • Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008 Jan;19(1):135-41.
  • Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Bea S, Gine E, Lopez-Guillermo A, Campo E, Montserrat E. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007; 109:2473-80
  • Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Gine E, Crespo M, Abrisqueta P, Moreno C, Cobo F, Lopez-Guillermo A, Montserrat E. Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic. Leukemia. J Clin Oncol 2007; 25:1576-80
  • Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose JM, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood. 2007;109(11):4599-606.
  • Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Beral H, Ghia P, Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109:259-70
  • Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006 Oct;17(10):1539-45
  • Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70:214-7
  • Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-9
  • Marce S, Balague O, Colomo L, Martinez A, Holler S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006; 12:3754-61.
  • Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood; 2006; 107:1276-83
  • Crespo M, Villamor N, Gine E, Muntanola A, Colomer D, Marafioti T, Jones M, Camos M, Campo E, Montserrat E, Bosch F. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006 12:726-34.
  • Plancarte F, Lopez-Guillermo A, Arenillas L, Montoto S, Gine E, Muntanola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006 76:58-63
  • Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, López-Guillermo A, Campo E, Sierra J, Montserrat E. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23(15):3433-8
  • López-Guillermo A, Colomo L, Jiménez L, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E. Diffuse large B-cell lymphoma: clinicobiological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23(12):2797-804
  • Hernández L, Beà S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, Bosch F, López-Guillermo A, Delabie J, Colomer D, Montserrat E, Campo E. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005; 65: 2199-206.
  • Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507-13.
  • Ferrer A, Marcé S, Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B, Solé F, Montserrat E, campo E, Colomer D. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.Oncogene 2004; 23: 8941-9.
  • Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Campo E, Sierra J, Montserrat E. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484-9.
  • Montagut C, Bosch F, Villela L, Rosinol L, Blade J. Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymph.2004 Aug;45(8):1711-2
  • Tort F, Camacho E, Bosch F, Lee Harris N, Montserrat E, Campo E. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004; 89:314-9
  • Martínez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expresion in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004;  164:501-510
  • Bosch F, Villamor N. ZAP-70 expression in chronic lymphocytic leukemia: a new parameter for an old disease. Haematologica 2003; 88:724-26.
  • Perea G, Altés A, Montoto S, López-Guillermo A, Bosch F, Jiménez M, Esteve J, Domingo E, Ribera JM, Pedro C, Martino R, Briones J, Sureda A, Brunet S, Sierra J, Montserrat E. International and Italian prognostic indices in follicular lymphoma. Haematologica 2003; 88: 700-4.
  • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75. (first and corresponding author)
  • Montoto S, Rozman M, Rosinol L, Nadal E, Gine E, Aymerich M, Ferrer A, Esteve J, Bosch F, Lopez-Guillermo A, Blade J, Montserrat E. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003 Apr;30(2):178-81
  • Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hemerlink KH, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, Feb; 3:185-197.
  • Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84
  • Montoto S, López-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E. Incidence and clinical significance of bcl-2/IgH rearrangement in follicular lymphoma. Leuk Lymph 2003; 44: 71-6.
  • Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altés A, Besalduch J, Ribera JM, Montserrat, for the GELCAB (Grup per l’Estudi dels Limfomes de Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-84.
  • Beà S, López-Guillermo A, Ribas M, Pinyol M, Carrió A, Soler F, Bosch F, Colomer D, Miró R, Montserrat E, Campo E. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large cell lymphoma (Richter’s syndrome). Am J Pathol 2002; 161: 957-68.
  • Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, Montserrat E, Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810-6.
  • Giné E, Bosch F, Villamor N, Rozman M, Colomer D, López-Guillermo A, Montserrat E. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia / small lymphocytic lymphoma: a frequent association? Leukemia 2002; 16: 1454-9.
  • Cobo F, Martínez A, Pinyol M, Hernández L, Gómez M, Beà S, Esteve J, Rozman M, Bosch F, López-Guillermo A, Montserrat E, Campo E. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia 2002; 16: 1028-34.
  • Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F, Giné E, Nadal E, Aymerich M, Rozman M, Montserrat E. Interleukin 6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 117:387-9
  • Montoto S, López-Guillermo A, Ferrer A, Camós M, Álvarez-Larrán A, Bosch F, Bladé J, Cervantes F, Esteve J, Cobo F, Colomer D, Campo E, Montserrat E. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002; 13: 523-30.
  • Gallart T, Benito C, Reverter JC, Bosch F, Blay M, Tassies D, Vigorito E, Cervera R, Font J, Gomis R, Campo E, Vives J. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002;116:875-86
  • Camacho E, Hernández L, Hernández S, Tort F, Bellosillo B, Beà S, Bosch F, Montserrat E, Cardesa A, Fernández PL, Campo E. ATM gene inactivation in mantle cell lymphoma mainly occur by truncating and missense mutations involving the PI-3 kinase domain. Blood 2002 99: 238-244.
  • Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, Binet JL, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258
  • Marti RM, Campo E, Bosch F, Palou J, Estrach T. Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. J Cutan Pathol 2001 28:256-64.
  • Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A, Dalla-Favera R. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97:2098-104
  • Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001; 91: 1557-62.
  • Sanz-Vaqué, Ll, Colomer D, Bosch F, López-Guillermo A, Dreyling MH, Ott G, Montserrat E, Campo E. Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica 2001; 86: 181-6..
  • Migliazza A, Cayanis E, Bosch F, et al. Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. Curr Top Microbiol Immunol. 2000;252:275-84.
  • Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Bladé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy C-MOPP/ABV as first line treatment in advanced stage Hodgkin’s disease. Cancer 2000; 88: 2142-8.
  • Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, Campo E. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia. 1999; 13:2087-93.
  • Cobo F, Hernández S, Hernández L, Pinyol M, Bosch F, Esteve J, López-Guillermo A, Palacín A, Raffeld M, Montserrat E, Jaffe ES, Campo E. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma ocurring in an HIV-seronegative patient. J Pathol 1999; 189: 288-93.
  • Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin’s lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999; 17: 1869-75.
  • Beà S, Ribas M, Hernández JM, Bosch F, Pinyol M, Hernández L, García JL, Flores T, González M, López-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miró R, Campo E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphomas are associated with blastoid variants. Blood 1999; 93: 4365-74.
  • Geisler C, Hansen MM, Yeap BY, Wiernik P, Binet JL, Chastang C, Dighiero G, Travade P, Jaksic B, Brugiatelli M, Kimby E, Catovsky D, Hamblin T, Richards S, Bosch F, Fontanillas M, Montserrat E, Alison R, Clarke M, Duong H, Elphinstone P, Evans V, Godwin J, Gray R, Greaves E, Hicks C, James S, Mead G, Peto R, Richards S, Wheatley K.  Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. J Natl Cancer Inst. 1999 May 19;91(10):861-8.
  • Ferrer A, López-Guillermo A, Bosch F, Montoto S, Hernández Boluda JC, Camós M, Miquél R, Campo E, Montserrat E. Linfomas del tejido linfoide asociado a mucosas (MALT) de localización extragástrica: análisis de 14 casos. Med Clin (Barc) 1999; 112: 577-80.
  • Espinet B, Sole F, Woessner S, Bosch F, Florensa L, Campo E, Costa D,Lloveras E, Vila RM, Besses C, Montserrat E, Sans-Sabrafen J. Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet 1999; 111:92-8.
  • Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158: 1889-93
  • López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, Fernández de Sevilla A, Bosch F, Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998; 9: 849-55.
  • Sanz L, López-Guillermo A, Martínez C, Bosch F, Esteve J, Cobo F, Montoto S, Perales M, Bladé J, Cervantes F, Campo E, Montserrat E. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. Eur J Haematol 1998; 61: 59-64.
  • Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Rozman C, Campo E, Montserrat E. Expression of the adhesion  molecule ICAM-1 (CD54) in non-Hodgkin’s lymphoma. Relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998; 16: 35-40.
  • Targarona EM, Espert JJ, Balague C, Sugranes G, Ayuso C, Lomena F, Bosch F, Trias M. Residual splenic function after laparoscopic splenectomy: a clinical concern. Arch  Surg 1998; 133:56-60.
  • Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 1997;8 1:93-101
  • Montserrat E, Bosch F, Rozman C. Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectivas. J Intern Med 242: 63-67 740, 1997
  • Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-75.
  • Esteve J, Villamor N, Colomer D, Bosch F, López-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E. Hematopoietic stem-cell transplantation for chronic lymphocytic leukemia. Report of 12 patients from a single institution. Ann Oncol 1998; 9: 167-72.
  • Rozman C, Bosch F, Montserrat E Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997 Jun;11(6):775-8.
  • Cervantes F, López-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996; 57: 286-91.
  • Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, López-Guillermo A, Bosch F, Hadjieu E, Rozman C. Tratamiento con fludarabina de neoplasias linfoides de bajo grado de malignidad resistenctes al tratamiento o en recaída. Med Clin 1996; 107: 86-9.
  • Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernández PL, Sánchez-Beato M, Soler F, Pérez-Losada A, Nayach I, Mallofré C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphoma. Correlation with Cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol, 1996; 148(5): 1591-1600.
  • Montserrat E, López-Lorenzo JL, Manso F, Martín A, Prieto E, Arias-Sampedro J, Fernández MN, Oyarzábal FJ, Odriozola J, Alcalà A, García-Conde J, Conde E, Guardia R, Bosch F. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish Group Experience. Leukemia and Lymphoma, 1996; 21:467-472.
  • Montserrat E, Villamor N, Reverter JC, Brugues RM, Tassies D, Bosch F, Aguilar JL, Vives-Corrons JL, Rozman M, Rozman C. Bone marrow assessment in B-cell chronic lymphocytic leukemia: aspirate or biopsy?. A comparative study in 258 patients. Br J Haematol, 1996; 93(1): 111-116.
  • Hernández L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffold M. p53 gene mutations and protein overexpression are associated with agressive variants of mantle cell lymphomas. Blood, 1996; 87(8): 3351-3359.
  • Esteve J, Cervantes F, Bosch F, Cobo F, Montserrat E, Rozman C. Tratamiento con interferón alfa del síndrome hipereosinofílico idiopático resistente a la terapéutica convencional. Med Clin, 1996; 106: 304-306.
  • Montserrat E, Bosch F, López-Guillermo A, Graus F, Terol MJ, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14: 941-4.
  • Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, Piris MA, DeWolf-Peeters C, Jaffe ES, Rozman C, Montserrat E, Cardesa A. Increased expression of the PRAD-1/CYCLIN D1 gene in hairy cell leukemia. Br J Haematol 1995; 91(4): 1025-1030.
  • Esteve J, López-Guillermo A, Martínez-Francés A, Bosch F, Terol MJ, Campo E, Montserrat E, Rozman C. Presenting features, natural history, and prognostic factors in localized non-Hodgkin’s lymphomas: analysis of 117 cases from a single institution. Eur J Haematol 1995; 55: 217-222.
  • Fraga M, Lloret E, Sánchez-Verde L, Orrade JL, Campo E, Bosch F, Piris MA. Mucosal mantle (centrocytic) lymphomas. Histopathology, 1995; 26: 413-422.
  • Martínez – Francés A; López – Guillermo A; Esteve J; Bosch F; Terol MJ; Montserrat E. Characteristics of patients with low grade malignant lymphoma and long survival. Sangre (Barc). 1995 Feb;40(1):53-7.
  • Bosch F, Jares P, Campo E, López-Guillermo A, Villamor N, Tassies D, Piris MA, Jaffe ES, Montserrat E, Rozman C, Cardesa A. PRAD-1/Cyclin D1 overexpression in lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84(8): 2726-2732.
  • Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a  series of 243 patients. Br J Haematol 1994; 88: 117-21.
  • López-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol MJ, Marín P, Reverter JC, Bladé J, Cervantes F, Sierra J, Rovira M, Nomdedeu B, Urbano-Ispizua A, Carreras E, Campo E, Rozman C. Low-grade lymphomas: clinical and prognostic studies in a series of 143 patients from a single institution. Leuk Lymph 1994; 15: 159-65.
  • Jares P, Fernández PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A. PRAD1/Cyclin D1 gene amplification correlates with mRNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994; 54: 4813-4817.
  • López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-8.
  • Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A, Yagüe J. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorrectal carcinomas. Cancer 1994; 73: 2913-2921.
  • Villamor N, Marín P, Aymerich M, Arriols R, Rovira M, Bosch F, Vilella R, Rozman C, Vives-Corrons JL. Diagnóstico de la hemoglobinuria paroxística nocturna mediante el análisis citofluorimétrico de moléculas unidas a membrana por grupos glucosilfosfatidilinositol. Med Clin 1994; 102: 481-484.
  • Cervantes F, Urbano-Ispízua A, Pujades A, Bosch F, Vives-Corrons JL, Montserrat E, Rozman C. Análisis molecular en la leucemia mieloide crónica cromosoma Filadelfia negativa: estudio de seis casos. Med Clin 1992; 99: 286-288
  • Sierra J, Grañena A, Bosch F, Carreras E, Martí JM, Urbano-Ispízua A, Rovira M, Rozman C. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. Hematol Oncol 1992; 10: 301-309.